Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...
New York, New York-- (Newsfile Corp. - February 7, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...
Novo Nordisk defends its obesity drug CagriSema despite disappointing late-stage trial data that significantly affected its market value. The company plans a new trial in 2025 due to positive ...
Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...
Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...
Novo Nordisk shares rose 4.5% after a strong Q4 profit beat, driven by high demand for obesity drug Wegovy, despite forecasting slower sales growth for 2025.
Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to scale down their dosing if, for example, they experienced side effects like ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback